The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders [1]

Blood

Volumn 106, Issue 8, 2005, Pages 2920-2921

  Scott, Linda M ^b   Campbell, Peter J ^b   Baxter, E Joanna ^b   Todd, Tony ^b   Stephens, Philip ^b   Edkins, Sarah ^b   Richard, Wooster ^b   Stratton, Michael R ^b   Futreal, P Andrew ^b   Green, Anthony R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; STAT PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; CANCER; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTOSIS; FISHER EXACT TEST; GENE MUTATION; HUMAN; HUMAN CELL; LETTER; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANK SUM TEST; THROMBOCYTHEMIA;

EID: 27144466017     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-05-2087     Document Type: Letter

References (10)

1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
5. Cools J, Peeters P, Veet T, et al. Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia. Cytogenet Cell Genet. 1999;85:260-266.
6. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65:2662-2667.
7. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535-2540.
8. Griesinger F, Podleschny M, Steffens R, et al. A novel BCR-JAK2 fusion gene is the result of a translocation (9;22)(p24;q11) in a case of CML [abstract]. Blood. 2000;96:352a.
9. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17:5321-5333.
10. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and preexisting myeloproliferative disorders. Br J Haematol. 2005;128:734-736.